By directly antagonizing BCL-2’s anti-apoptotic action, Venetoclax reinstates the natural cellular process of apoptosis, particularly in cells like Multiple Myeloma cells that have aberrant BCL-2 expression. The gene discussed is BCL2; the disease is plasma cell myeloma.